About: Gandotinib

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Gandotinib (LY-2784544) is an experimental drug developed by Eli Lilly for treatment of cancer. It is a small molecule JAK2 (Janus kinase) inhibitor, with additional minor inhibition of STAT3. In a phase I trial, 16% of patients receiving the drug developed tumor lysis syndrome. A phase II trial is underway for patients with myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, or myelofibrosis, who had failed ruxolitinib.

Property	Value
dbo:abstract	Gandotinib (LY-2784544) is an experimental drug developed by Eli Lilly for treatment of cancer. It is a small molecule JAK2 (Janus kinase) inhibitor, with additional minor inhibition of STAT3. In a phase I trial, 16% of patients receiving the drug developed tumor lysis syndrome. A phase II trial is underway for patients with myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, or myelofibrosis, who had failed ruxolitinib. (en)
dbo:casNumber	1229236-86-5
dbo:fdaUniiCode	ANC71R916O
dbo:kegg	D10365
dbo:pubchem	46213929
dbo:thumbnail	wiki-commons:Special:FilePath/Gandotinib.svg?width=300
dbo:wikiPageID	52838446 (xsd:integer)
dbo:wikiPageLength	3421 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1028561294 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Ruxolitinib dbr:Eli_Lilly dbr:Myelofibrosis dbc:Experimental_cancer_drugs dbr:Tumor_lysis_syndrome dbc:Pyrazoles dbr:Essential_thrombocythemia dbc:Morpholines dbr:STAT3 dbr:Polycythemia_vera dbr:JAK2 dbr:Myeloproliferative_neoplasms
dbp:atcPrefix	none (en)
dbp:c	23 (xsd:integer)
dbp:casNumber	1229236 (xsd:integer)
dbp:chemspiderid	25027412 (xsd:integer)
dbp:cl	1 (xsd:integer)
dbp:f	1 (xsd:integer)
dbp:h	25 (xsd:integer)
dbp:iupacName	3 (xsd:integer)
dbp:kegg	D10365 (en)
dbp:n	7 (xsd:integer)
dbp:o	1 (xsd:integer)
dbp:pubchem	46213929 (xsd:integer)
dbp:routesOfAdministration	PO (en)
dbp:smiles	C12CCN1CCOCC1 (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	SQSZANZGUXWJEA-UHFFFAOYSA-N (en)
dbp:unii	ANC71R916O (en)
dbp:wikiPageUsesTemplate	dbt:Infobox_drug dbt:Reflist dbt:Cascite dbt:Fdacite
dcterms:subject	dbc:Experimental_cancer_drugs dbc:Pyrazoles dbc:Morpholines
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	Gandotinib (LY-2784544) is an experimental drug developed by Eli Lilly for treatment of cancer. It is a small molecule JAK2 (Janus kinase) inhibitor, with additional minor inhibition of STAT3. In a phase I trial, 16% of patients receiving the drug developed tumor lysis syndrome. A phase II trial is underway for patients with myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, or myelofibrosis, who had failed ruxolitinib. (en)
rdfs:label	Gandotinib (en)
owl:sameAs	yago-res:Gandotinib wikidata:Gandotinib https://global.dbpedia.org/id/2Y3dm
prov:wasDerivedFrom	wikipedia-en:Gandotinib?oldid=1028561294&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Gandotinib.svg
foaf:isPrimaryTopicOf	wikipedia-en:Gandotinib
is dbo:wikiPageWikiLink of	dbr:Janus_kinase_inhibitor
is foaf:primaryTopic of	wikipedia-en:Gandotinib